MGUS management by the general practitioner
Article Sidebar
Main Article Content
Abstract
Monoclonal gammopathy of undetermined significance ( MGUS ) is an haematologic condition, most often incidental. It is considered an obligate precursor to several lymphoplasmacytic malignancies. Since long-term follow-up is generally recommended, General Practitioner ( GP ) follows the patient based on risk stratification in order to organize clinical and laboratory checks.
GP often is the first healthcare professional to whom patients report symptoms of progression. GPs can manage these patients but collaboration with haematological specialists is necessary in order to identify doubtful suspects of progression and avoid improper referrals to specialists. It is important to implement the awareness and knowledge of the role of GPs with the support of guidelines and appropriate informative material dedicated to MGUS.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Brown LM (2008). Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood. 111:3388-3394.
Alexander DD (2007). Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 120 (suppl 12):40-61.
Kyle RA (2006). Prevalence of Monoclonal Gammopathy of Undetermined Significance. NEJM. 354:1362-1369 .
Ronald S Go (2017). How I manage monoclonal gammopathy of undetermined significance . Blood. 131(2).
Kyle RA (1978). Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med. 64:814-826.
Landgren O (2017). Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey . Blood Cancer j. 7(10):e 618.
Landgren O (2014). Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 28 (7).
Vachom CM (2009). Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 114(4):785-90.
Schroeder ,Cl. Biochemistry, 2023.
International Myeloma Working Group (2003) Br.J.haematol. 121:749-7579.
Kyle RA et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance . N eng j med . 346(8):564-9.
Vaxman I (2020) When to Suspect a Diagnosis of Amyloidosis. Acta Haematol . 143(4):304-311.
Gertz MA (2020). Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review. JAMA. Jul 7;324(1):79-89.
Amyloidosis Support Group, 4th International ATTR Amyloidosis Meeting. Category: External Event 03-2023 .
Amyloidosis Support Group, 4th International ATTR Amyloidosis Meeting. Category: External Event 03-2023
Angioi A (2023). Classification and management of MGRS related diseases. G Ital Nefrol. 40(Suppl 81): 2023-S81.
Gnanasampanthan S (2023). Monoclonal gammopathies of renal significance. Clinical Medicine Journal. 23(3):250-253.
European Myeloma Network(2014). European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Feb;99(2):232-42.
Rao M (2012). Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs: Identification of Future Research Needs From Comparative. Free Books & Documents. Report No.: 12-EHC135-EF.
Mangiacavalli S (2013). Monoclonal gammopathy of undetermined significance: a new proposal of workup .Eur.J.Haemat. 91(4):356-60.
Mouhieddine TH (2019). Monoclonal gammopathy of undetermined significance.Blood. 133(23):2484-2494 .
Bruehl F.K (2023). IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders. Haematologica. Vol. 108 No. 10 (2023): October.
Linfeng LI (2023). Nutritional Status Indices and Monoclonal Gammopathy of Undetermined Significance Risk in the Elderly Population: Findings from the National Health and Nutrition Examination Survey. Nutriens . 15(19), 4210.